ActiQs / Forskning

PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för vadimezan. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

16 träffar

Bibliografisk träff 2013-03-12

Using macrophage activation to augment immunotherapy of established tumours.

Fridlender ZG, Jassar A, Mishalian I, Wang LC, Kapoor V, Cheng G, Sun J, Singhal S, Levy L, Albelda SM.

Br J Cancer · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1038/bjc.2013.93

Bibliografisk träff 2013-03-12

Identification of human-selective analogues of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).

Tijono SM, Guo K, Henare K, Palmer BD, Wang LC, Albelda SM, Ching LM.

Br J Cancer · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1038/bjc.2013.101

Bibliografisk träff 2012-06-13

The influence of the combined treatment with Vadimezan (ASA404) and taxol on the growth of U251 glioblastoma xenografts.

Milanović D, Braun F, Weber W, Grosu AL, Behe M, Niedermann G.

BMC Cancer · research support, non-u.s. gov't; research-article; journal article · DOI 10.1186/1471-2407-12-242

Bibliografisk träff 2012-05-01

DMXAA (Vadimezan, ASA404) is a multi-kinase inhibitor targeting VEGFR2 in particular.

Buchanan CM, Shih JH, Astin JW, Rewcastle GW, Flanagan JU, Crosier PS, Shepherd PR.

Clin Sci (Lond) · research support, non-u.s. gov't; journal article · DOI 10.1042/cs20110412

Bibliografisk träff 2011-08-26

Pharmacokinetic evaluation of vadimezan (ASA404, 5,6-dimethylxanthenone-4-acetic acid, DMXAA).

Jameson MB, Head M.

Expert Opin Drug Metab Toxicol · review; journal article · DOI 10.1517/17425255.2011.614389

Bibliografisk träff 2011-07-26

Activation of mitogen-activated protein kinases by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) plays an important role in macrophage stimulation.

Sun J, Wang LC, Fridlender ZG, Kapoor V, Cheng G, Ching LM, Albelda SM.

Biochem Pharmacol · research-article; journal article; research support, n.i.h., extramural · DOI 10.1016/j.bcp.2011.07.086

Bibliografisk träff 2011-06-27

Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer.

Lara PN, Douillard JY, Nakagawa K, von Pawel J, McKeage MJ, Albert I, Losonczy G, Reck M, Heo DS, Fan X, Fandi A, Scagliotti G.

J Clin Oncol · clinical trial, phase iii; randomized controlled trial; journal article · DOI 10.1200/jco.2011.35.0660

Bibliografisk träff 2011-06-13

Aminolevulinic acid-photodynamic therapy combined with topically applied vascular disrupting agent vadimezan leads to enhanced antitumor responses.

Marrero A, Becker T, Sunar U, Morgan J, Bellnier D.

Photochem Photobiol · research-article; journal article; research support, n.i.h., extramural · DOI 10.1111/j.1751-1097.2011.00943.x

Bibliografisk träff 2011-05-14

Developing a robust ultrafiltration-LC-MS/MS method for quantitative analysis of unbound vadimezan (ASA404) in human plasma.

Li W, Lin H, Smith HT, Tse FL.

J Chromatogr B Analyt Technol Biomed Life Sci · journal article · DOI 10.1016/j.jchromb.2011.05.012

Bibliografisk träff 2011-02-14

18F-fluromisonidazole PET imaging as a biomarker for the response to 5,6-dimethylxanthenone-4-acetic acid in colorectal xenograft tumors.

Oehler C, O'Donoghue JA, Russell J, Zanzonico P, Lorenzen S, Ling CC, Carlin S.

J Nucl Med · research-article; journal article; research support, n.i.h., extramural · DOI 10.2967/jnumed.110.081372

Bibliografisk träff 2011-02-08

Phase I study of intravenous ASA404 (vadimezan) administered in combination with paclitaxel and carboplatin in Japanese patients with non-small cell lung cancer.

Hida T, Tamiya M, Nishio M, Yamamoto N, Hirashima T, Horai T, Tanii H, Shi MM, Kobayashi K, Horio Y.

Cancer Sci · research support, non-u.s. gov't; clinical trial, phase i; journal article · DOI 10.1111/j.1349-7006.2010.01839.x

Bibliografisk träff 2010-07-21

Vadimezan: 2-(5,6-dimethyl-9-oxo-9H-xanthen-4-yl)acetic acid.

Zhang SJ, Hu WX.

Acta Crystallogr Sect E Struct Rep Online · research-article; journal article · DOI 10.1107/s1600536810028394

Bibliografisk träff 2010-05-11

Phase II study on the addition of ASA404 (vadimezan; 5,6-dimethylxanthenone-4-acetic acid) to docetaxel in CRMPC.

Pili R, Rosenthal MA, Mainwaring PN, Van Hazel G, Srinivas S, Dreicer R, Goel S, Leach J, Wong S, Clingan P.

Clin Cancer Res · clinical trial, phase ii; research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1158/1078-0432.ccr-09-3026

Bibliografisk träff 2010-02-01

The development of the tumor vascular-disrupting agent ASA404 (vadimezan, DMXAA): current status and future opportunities.

Head M, Jameson MB.

Expert Opin Investig Drugs · journal article · DOI 10.1517/13543780903540214

Bibliografisk träff 2010-01-29

Activation of the nucleotide oligomerization domain signaling pathway by the non-bacterially derived xanthone drug 5'6-dimethylxanthenone-4-acetic acid (Vadimezan).

Cheng G, Sun J, Fridlender ZG, Wang LC, Ching LM, Albelda SM.

J Biol Chem · research-article; journal article; research support, n.i.h., extramural · DOI 10.1074/jbc.m109.065631

Bibliografisk träff 2009-11-01

Molecule of the month. Vadimezan.

Författaruppgift saknas

Drug News Perspect · journal article